Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

If you’re pregnant or hoping to become pregnant, it’s natural to have questions about your medications. And if you’re taking ...

On this news, Novo Nordisk's stock price fell $15.06, or 21.8%, to close at $53.94 per share on July 2, 2025, thereby injuring investors. What Is The Lawsuit About?

There's been an all-out push by the drug regulators and media to get every adult and child on Ozempic, a drug which causes temporary weight loss and harms the majority of recipients. Here, two leading ...

Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and ...

Chinese drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...

Health officials have issued yet another warning over the perils of fake weight loss jabs after an influencer nearly died ...

Novo Nordisk, GSK and others need to replenish their pipelines to replace drugs coming off patent. In the past, buying a promising biotech required paying a 100% premium. But high interest rates and ...

The Securities and Exchange Commission, overseen by crypto millionaire Paul Atkins, just agreed to drop its lawsuit against ...

A groundbreaking initiative from the Trump administration could revolutionize access to costly weight-loss drugs under ...

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results ...